Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avanos Medical (AVNS) Long-Term Deferred Tax (2016 - 2025)

Avanos Medical (AVNS) has disclosed Long-Term Deferred Tax for 12 consecutive years, with $33.1 million as the latest value for Q4 2025.

  • Quarterly Long-Term Deferred Tax rose 32.93% to $33.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $33.1 million through Dec 2025, up 32.93% year-over-year, with the annual reading at $33.1 million for FY2025, 32.93% up from the prior year.
  • Long-Term Deferred Tax hit $33.1 million in Q4 2025 for Avanos Medical, up from $25.3 million in the prior quarter.
  • In the past five years, Long-Term Deferred Tax ranged from a high of $61.9 million in Q2 2021 to a low of $4.3 million in Q3 2023.
  • Historically, Long-Term Deferred Tax has averaged $16.1 million across 5 years, with a median of $11.0 million in 2022.
  • Biggest five-year swings in Long-Term Deferred Tax: soared 342.14% in 2021 and later tumbled 82.07% in 2022.
  • Year by year, Long-Term Deferred Tax stood at $10.0 million in 2021, then tumbled by 54.0% to $4.6 million in 2022, then soared by 41.3% to $6.5 million in 2023, then surged by 283.08% to $24.9 million in 2024, then surged by 32.93% to $33.1 million in 2025.
  • Business Quant data shows Long-Term Deferred Tax for AVNS at $33.1 million in Q4 2025, $25.3 million in Q3 2025, and $25.3 million in Q2 2025.